Literature DB >> 7467397

The polymorphic 4-hydroxylation of debrisoquine in a Saudi arab population.

S I Islam, J R Idle, R L Smith.   

Abstract

1. Debrisoquine 4-hydroxylation was polymorphic in 102 Saudi arab volunteers, the population comprising one phenotypically poor metabolizer and 101 phenotypically extensive metabolizers of debrisoquine. 2. Mean urinary recoveries of drug and metabolite were low in Saudis (15 +/- 10% dose, mean +/- S.D.), which compared well with previously studied populations of Egyptians (16%) and Ghanaians (18%), but which were lower than those seen in a UK white population (41%). 3. Saudis, like Egyptians, were more extensive metabolizers of debrisoquine than UK whites, as judged by the metabolic ratio (% dose as debrisoquine/% dose as 4-hydroxy-debrisoquine eliminated in the urine). 4. Neither sex, urine collection period nor urinary recovery of drug and metabolite had any statistically significant effect upon the distribution of metabolic ratios in Saudis. 5. The frequency of the DL allele controlling the recessive poor metabolizer trait was 0.099 +/- 0.049 (+/- S.E.M.) in Saudis, which compared well to Egyptians (0.118 +/- 0.059) but was significantly lower than that for UK whites (0.298 +/- 0.030). 6. These findings raise questions regarding the efficacy and safety in Saudis of drugs undergoing oxidative metabolism which have been evaluated for usage in European white subjects.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7467397     DOI: 10.3109/00498258009033812

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  17 in total

1.  Genetic polymorphism of CYP2D6 in a keralite (South India) population.

Authors:  B K Abraham; C Adithan; C H Shashindran; S Vasu; N A Alekutty
Journal:  Br J Clin Pharmacol       Date:  2000-03       Impact factor: 4.335

2.  Polymorphism of debrisoquine oxidation in New Zealand Caucasians.

Authors:  S Wanwimolruk; J R Denton; D G Ferry; M Beasley; J R Broughton
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 3.  Ethnic differences in drug disposition and responsiveness.

Authors:  A J Wood; H H Zhou
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

4.  Evidence for the polymorphic oxidation of debrisoquine and proguanil in a Khmer (Cambodian) population.

Authors:  S Wanwimolruk; M R Thou; D J Woods
Journal:  Br J Clin Pharmacol       Date:  1995-08       Impact factor: 4.335

5.  Statistical analysis of polymorphic drug metabolism data using the Rosin Rammler Sperling Weibull distribution.

Authors:  D B Jack
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

6.  Genetically determined sparteine oxidation polymorphism in a Polish population.

Authors:  K Orzechowska-Juzwenko; J Pawlik; P Niewiński; P Milejski; J Dembowski; J Turek; A Goździk; L Swiebodzki; Z Hora
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

Review 7.  Ethnic differences in drug metabolism.

Authors:  W Kalow
Journal:  Clin Pharmacokinet       Date:  1982 Sep-Oct       Impact factor: 6.447

8.  Dextromethorphan O-demethylation polymorphism in Jordanians.

Authors:  Y M Irshaid; H F al-Hadidi; N M Rawashdeh
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

9.  Debrisoquine oxidation polymorphism in a Tasmanian population.

Authors:  M E Veronese; S McLean
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 10.  Steady-state kinetics of doxepin and imipramine in Saudi patients with interethnic comparison.

Authors:  A el-Yazigi; K Chaleby
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.